AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37228005 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine CXCL10 monitoring with elevated values triggering allograft biopsy and therapeutic adaptations (per-protocol analysis).
Number of subjects: 241
Study 37228005 — intervention group
Group type: COMPARATOR
Intervention: Urine CXCL10 monitoring (results concealed) (per-protocol analysis).
Number of subjects: 241
Study 37228011 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 68
Study 37228011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 37228028 — intervention group
Group type: COMPARATOR
Intervention: Intravenous belimumab 10 mg/kg
Number of subjects: 3225
Study 37228028 — intervention group
Group type: COMPARATOR
Intervention: Intravenous belimumab 1 mg/kg
Number of subjects: 3225
Study 37228028 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous belimumab 200 mg
Number of subjects: 3225
Study 37228028 — intervention group
Group type: COMPARATOR
Intervention: Antimalarial agents (AMA)
Number of subjects: 3225
Study 37228028 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intravenous belimumab 1 mg/kg and AMA
Number of subjects: 3225
Study 37228030 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3)
Number of subjects: 109
Study 37228030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 37228142 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted environmental control intervention (dynamic light therapy, auditory masking, rationalization of ICU nocturnal patient care activities)
Number of subjects: 56
Study 37228142 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 56
Study 37228726 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative meta-synthesis based on patients' narratives from qualitative studies
Number of subjects: 167
Study 37228726 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative meta-synthesis
Number of subjects: 167
Study 37228786 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop central thalamic deep brain stimulation (CT-DBS)
Number of subjects: 0
Study 37228816 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37229174 — intervention group
Group type: EXPERIMENTAL
Intervention: Casirivimab plus Imdevimab (CAS + IMD)
Number of subjects: 99
Study 37229174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 37229650 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib (BARI) 4 mg/day for 52 weeks
Number of subjects: 30
Study 37229775 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of elemental oral iron (18.6 mg ferrous sulphate) twice daily for 8 weeks
Number of subjects: 36
Study 37229879 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin dosing based on Jelliffe formula
Number of subjects: 3830
Study 37229879 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin dosing based on MDRD and Cockcroft-Gault formulas
Number of subjects: 3830
Study 37229879 — intervention group
Group type: EXPERIMENTAL
Intervention: NCCN guidelines for estimating renal function
Number of subjects: 3830
Study 37230101 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental dolutegravir (50 mg 12 h later)
Number of subjects: 108
Study 37230101 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched placebo 12 h later)
Number of subjects: 108
Study 37230105 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care CRP testing plus routine care
Number of subjects: 39856
Study 37230105 — intervention group
Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 39856
Study 37230105 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care CRP testing plus routine care (per-protocol analysis)
Number of subjects: 39856
Study 37230168 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated contingency management with stepped care
Number of subjects: 0
Study 37230168 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 37230366 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous upadacitinib 30 mg
Number of subjects: 484
Study 37230366 — intervention group
Group type: COMPARATOR
Intervention: Switching from dupilumab to upadacitinib 30 mg
Number of subjects: 484
Study 37230383 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach A (data-driven, hypothesis-free)
Number of subjects: 6720
Study 37230383 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach B (unsupervised Random Forest guided by clinical input)
Number of subjects: 6720
Study 37230383 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 6720
Study 37230515 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide flooding of the surgical field
Number of subjects: 80
Study 37230515 — intervention group
Group type: COMPARATOR
Intervention: Control group (no carbon dioxide flooding)
Number of subjects: 80
Study 37230521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC)
Number of subjects: 0
Study 37230521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37230524 — intervention group
Group type: EXPERIMENTAL
Intervention: One oral loading dose of 100,000 IU vitamin D
Number of subjects: 0
Study 37230524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37230523 — intervention group
Group type: COMPARATOR
Intervention: Standard care with 0 sessions of HBOT
Number of subjects: 0
Study 37230523 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care with 20 sessions of HBOT
Number of subjects: 0
Study 37230523 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care with 30 sessions of HBOT
Number of subjects: 0
Study 37230523 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care with at least 40 sessions of HBOT
Number of subjects: 0
Study 37230523 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 37230752 — intervention group
Group type: EXPERIMENTAL
Intervention: Agricultural, animal husbandry worker (ISCO: 6-2)
Number of subjects: 454
Study 37230752 — intervention group
Group type: EXPERIMENTAL
Intervention: Salesman (ISCO: 4-51)
Number of subjects: 454
Study 37230752 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical fitters and related, electrical and electronics workers employed for 2 years or more (ISCO: 8-5)
Number of subjects: 454
Study 37230851 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in fruit and vegetables (measured by carotene plasma concentrations)
Number of subjects: 204
Study 37230851 — intervention group
Group type: EXPERIMENTAL
Intervention: Total carotene
Number of subjects: 204
Study 37230851 — intervention group
Group type: EXPERIMENTAL
Intervention: α-carotene
Number of subjects: 204
Study 37230851 — intervention group
Group type: EXPERIMENTAL
Intervention: β-carotene
Number of subjects: 204
Study 37230851 — intervention group
Group type: EXPERIMENTAL
Intervention: β-carotene and total carotene
Number of subjects: 204
Study 37230961 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 48832
Study 37230961 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 48832
Study 37231074 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 917
Study 37231074 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 917
Study 37231074 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 917
Study 37231074 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 917
Study 37231080 — intervention group
Group type: EXPERIMENTAL
Intervention: Mescaline 500 mg
Number of subjects: 32
Study 37231080 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD 100 µg
Number of subjects: 32
Study 37231080 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin 20 mg
Number of subjects: 32
Study 37231080 — intervention group
Group type: EXPERIMENTAL
Intervention: Mescaline 300 mg
Number of subjects: 32
Study 37231080 — intervention group
Group type: EXPERIMENTAL
Intervention: Mescaline and LSD
Number of subjects: 32
Study 37231080 — intervention group
Group type: EXPERIMENTAL
Intervention: None of the substances
Number of subjects: 32
Study 37231094 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37231221 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 64
Study 37231221 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 64
Study 37231296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir with ritonavir (PAXLOVID™)
Number of subjects: 0
Study 37231296 — intervention group
Group type: COMPARATOR
Intervention: Nirmatrelvir without ritonavir (control)
Number of subjects: 0
Study 37231350 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AG09222 + PACAP38 infusion
Number of subjects: 25
Study 37231350 — intervention group
Group type: COMPARATOR
Intervention: Placebo + PACAP38 infusion
Number of subjects: 25
Study 37231350 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AG09222
Number of subjects: 25
Study 37231386 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported self-management (SSM)
Number of subjects: 1000
Study 37231386 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation therapy (SMT)
Number of subjects: 1000
Study 37231386 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SSM and SMT
Number of subjects: 1000
Study 37231386 — intervention group
Group type: COMPARATOR
Intervention: Medical care
Number of subjects: 1000
Study 37231390 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized rTMS synchronized to the trough of the sensorimotor µ-oscillation
Number of subjects: 144
Study 37231390 — intervention group
Group type: COMPARATOR
Intervention: Standard rTMS (non-synchronized)
Number of subjects: 144
Study 37231390 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (ineffective rTMS)
Number of subjects: 144
Study 37231445 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term exposure to ambient fine particulate matter (PM ≤ 2.5 µm)
Number of subjects: 10142
Study 37231445 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term exposure to ambient fine particulate matter (PM ≤ 2.5 µm)
Number of subjects: 10142
Study 37231477 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth application for ORL patients and caregivers during the perioperative period
Number of subjects: 180
Study 37231477 — intervention group
Group type: COMPARATOR
Intervention: Standard care (oral information and brochures)
Number of subjects: 180
Study 37231479 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-release extended-release naltrexone (XR-NTX) + referral to community XR-NTX
Number of subjects: 0
Study 37231479 — intervention group
Group type: COMPARATOR
Intervention: Referral only
Number of subjects: 0
Study 37231634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent physical exercise training (IPET) for 1 hour weekly during paid working hours for 2 years, plus recommendations for 30-minute leisure time physical activity 6 days/week (LPA)
Number of subjects: 387
Study 37231634 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 387
Study 37231670 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P47 (162 mg/0.9 mL, single subcutaneous dose)
Number of subjects: 289
Study 37231670 — intervention group
Group type: COMPARATOR
Intervention: EU-tocilizumab (single subcutaneous dose)
Number of subjects: 289
Study 37231670 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P47
Number of subjects: 289
Study 37231670 — intervention group
Group type: COMPARATOR
Intervention: EU-tocilizumab
Number of subjects: 289
Study 37231682 — intervention group
Group type: EXPERIMENTAL
Intervention: BGC balloon inflation during EVT
Number of subjects: 124
Study 37231682 — intervention group
Group type: COMPARATOR
Intervention: No balloon inflation during EVT
Number of subjects: 124
Study 37231838 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 0
Study 37231977 — intervention group
Group type: EXPERIMENTAL
Intervention: DPA duration variability
Number of subjects: 126
Study 37231977 — intervention group
Group type: EXPERIMENTAL
Intervention: DPA performance variability
Number of subjects: 126
Study 37232002 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine (10 or 20 mg/day)
Number of subjects: 201
Study 37232002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 37232058 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 685509
Number of subjects: 0
Study 37232058 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37232393 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 613
Study 37232393 — intervention group
Group type: COMPARATOR
Intervention: Non-statin therapy
Number of subjects: 613
Study 37232425 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-IVUS-guided primary PCI
Number of subjects: 200
Study 37232430 — intervention group
Group type: EXPERIMENTAL
Intervention: ccIIV4
Number of subjects: 230
Study 37232430 — intervention group
Group type: COMPARATOR
Intervention: LAIV4
Number of subjects: 230
Study 37232493 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home HPV self-sampling kits
Number of subjects: 233
Study 37232534 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management strategies and medications (prescription and over-the-counter)
Number of subjects: 11
Study 37232534 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare provider assessment and support
Number of subjects: 11
Study 37232853 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger cuff system (ClearSight; Edward Lifesciences)
Number of subjects: 130
Study 37232853 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper arm measurements
Number of subjects: 130
Study 37232853 — intervention group
Group type: COMPARATOR
Intervention: Lower leg measurements
Number of subjects: 130
Study 37232853 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-cardiovascular intervention measurements at all sites
Number of subjects: 130
Study 37232940 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose 10 mg/kg of L-AmB
Number of subjects: 118
Study 37232940 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg of L-AmB on D1, and 5 mg/kg of L-AmB on D3
Number of subjects: 118
Study 37232940 — intervention group
Group type: COMPARATOR
Intervention: 3 mg/kg of L-AmB daily for 2 weeks (control)
Number of subjects: 118
Study 37233207 — intervention group
Group type: EXPERIMENTAL
Intervention: cTACE
Number of subjects: 28
Study 37233785 — intervention group
Group type: EXPERIMENTAL
Intervention: PET agent A
Number of subjects: 50
Study 37233785 — intervention group
Group type: COMPARATOR
Intervention: PET agent B
Number of subjects: 50
Study 37233882 — intervention group
Group type: EXPERIMENTAL
Intervention: Low plasma adropin concentrations
Number of subjects: 452
Study 37233882 — intervention group
Group type: EXPERIMENTAL
Intervention: Adropin tertiles (1st to 3rd)
Number of subjects: 452
Study 37233888 — intervention group
Group type: EXPERIMENTAL
Intervention: ICC-T (Interaction Competencies with Children-for Teachers)
Number of subjects: 173
Study 37233888 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 173
Study 37233897 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily
Number of subjects: 90
Study 37233897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 37233987 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus Trametinib
Number of subjects: 53
Study 37234006 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy (MT) in NICU
Number of subjects: 206
Study 37234006 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy (MT) postdischarge
Number of subjects: 206
Study 37234006 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of MT in NICU and MT postdischarge
Number of subjects: 206
Study 37234014 — intervention group
Group type: EXPERIMENTAL
Intervention: Free medicine distribution (access to 128 medicines with no out-of-pocket costs for 3 years)
Number of subjects: 747
Study 37234014 — intervention group
Group type: COMPARATOR
Intervention: Usual medicine access
Number of subjects: 747
Study 37234760 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing counseling
Number of subjects: 0
Study 37234760 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated text messages and quiz questions about HIV management (21 weeks)
Number of subjects: 0
Study 37234760 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial rewards for viral suppression (lottery prize vs. fixed compensation)
Number of subjects: 0
Study 37234760 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral suppression
Number of subjects: 0
Study 37235505 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts
Number of subjects: 1988
Study 37235505 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Number of subjects: 1988
Study 37235505 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 1988
Study 37235505 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate
Number of subjects: 1988
Study 37235505 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stimulant exposure)
Number of subjects: 1988
Study 37235629 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-invaded lung tissue
Number of subjects: 23
Study 37235629 — intervention group
Group type: COMPARATOR
Intervention: Non-invaded lung tissue
Number of subjects: 23
Study 37235690 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab plus corticosteroids
Number of subjects: 75
Study 37235690 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids alone (Control)
Number of subjects: 75
Study 37235836 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 74
Study 37235836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 37235845 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body PET-CT
Number of subjects: 369
Study 37235845 — intervention group
Group type: COMPARATOR
Intervention: Conventional staging
Number of subjects: 369
Study 37235976 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 345
Study 37235976 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (Cisplatin plus Pemetrexed)
Number of subjects: 345
Study 37236007 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy with agalsidase beta
Number of subjects: 8000
Study 37236033 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib 225 mg BID orally for 2.5 days and carboplatin AUC 5 mg/ml·min intravenously
Number of subjects: 32
Study 37236221 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine plus tafenoquine (300 mg)
Number of subjects: 150
Study 37236221 — intervention group
Group type: COMPARATOR
Intervention: dihydroartemisinin-piperaquine alone
Number of subjects: 150
Study 37236221 — intervention group
Group type: EXPERIMENTAL
Intervention: primaquine (15 mg) plus dihydroartemisinin-piperaquine
Number of subjects: 150
Study 37236246 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapeutic intervention over 48 weeks
Number of subjects: 173
Study 37236246 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline fatigue
Number of subjects: 173
Study 37236246 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HRQoL
Number of subjects: 173
Study 37236398 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily for up to 3 years
Number of subjects: 680
Study 37236398 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 680
Study 37236398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 680
Study 37236549 — intervention group
Group type: COMPARATOR
Intervention: Standardized low-fat diet
Number of subjects: 156
Study 37236549 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized diet
Number of subjects: 156
Study 37236636 — intervention group
Group type: EXPERIMENTAL
Intervention: M9241 at 4, 8, 12, or 16.8 µg/kg every 4 weeks plus avelumab 10 mg/kg every 2 weeks (dose levels 1-4)
Number of subjects: 52
Study 37236636 — intervention group
Group type: EXPERIMENTAL
Intervention: M9241 16.8 µg/kg every 4 weeks plus avelumab 800 mg once a week for 12 weeks followed by every 2 weeks (DL5/dose expansion)
Number of subjects: 52
Study 37236636 — intervention group
Group type: EXPERIMENTAL
Intervention: M9241 plus avelumab (all dose levels)
Number of subjects: 52
Study 37236666 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic single dose of fibrinogen, in addition to standard of care
Number of subjects: 32
Study 37236666 — intervention group
Group type: COMPARATOR
Intervention: Standard of care without study medication prior to skin incision
Number of subjects: 32
Study 37236706 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-radiation therapy (RT) characteristics
Number of subjects: 572
Study 37236706 — intervention group
Group type: EXPERIMENTAL
Intervention: Time between extraction and start of RT
Number of subjects: 572
Study 37236829 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 201
Study 37236877 — intervention group
Group type: EXPERIMENTAL
Intervention: Beeswax
Number of subjects: 90
Study 37236877 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 90
Study 37236877 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 37236899 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine microneedle patches
Number of subjects: 50
Study 37236899 — intervention group
Group type: COMPARATOR
Intervention: Ionotophoresis
Number of subjects: 50
Study 37236995 — intervention group
Group type: EXPERIMENTAL
Intervention: PTX-COVID19-B vaccine (16-µg, 40-µg, or 100-µg doses)
Number of subjects: 60
Study 37236995 — intervention group
Group type: EXPERIMENTAL
Intervention: PTX-COVID19-B vaccine (all doses)
Number of subjects: 60
Study 37236995 — intervention group
Group type: EXPERIMENTAL
Intervention: PTX-COVID19-B vaccine (40-µg dose)
Number of subjects: 60
Study 37237172 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3368715 (50, 100, and 200 mg)
Number of subjects: 31